ARVN Comptes : Analyse IA Arvinas Inc



Comptes financiers

ARVN Financier

Arvinas Inc

$10.22

-0.68%

$-0.06

À la fermeture : Apr 28, 16:00:00 GMT-4

$10.21

-0.09%

$0

Pré-Marché: Apr 29, 08:10:00 GMT-4

Aperçu Prévision Gagner Dividendes Comptes financiers

Statistiques clés

Clôture préc.

$10.29

Prix d'ouverture

$10.38

Plage de la journée

$10.16 - $10.51

Plage de 52 semaines

$5.9 - $14.51

Volume

401.3K

Volume moyen

860.0K

Rendement en dividend

BPA (TTM)

-1.22

Capitalisation boursière

$653.0M

Qu’est-ce que ARVN ?

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is headquartered in New Haven, Connecticut and currently employs 246 full-time employees. The company went IPO on 2018-09-27. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. The company is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.

Revenus

État de situation

Flux de trésorerie

Annuel

Trimestriellement

ARVN Revenu

Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.

Breakdown	TTM	12/31/2025	09/30/2025	06/30/2025	03/31/2025	12/31/2024
Revenus	262	9	41	22	188	59
Croissance des revenus (H/H)	0%	-85%	-60%	-71%	652%	-24%
Coût des ventes	--	--	--	--	--	--
Bénéfice brut	--	--	--	--	--	--
Vente, Général et Administration	95	23	21	25	26	34
Recherche et développement	285	61	64	68	90	83
Frais d'exploitation	378	81	85	93	117	117
Autres revenus (charges) non opérationnels	0	0	0	0	--	0
Bénéfice avant impôts	-80	-67	-34	-61	83	-46
Charge d'impôt sur le revenu	0	0	0	0	0	0
Bénéfice net	-80	-67	-35	-61	82	-45
Croissance du bénéfice net	-60%	49%	-28.99%	74%	-219%	-88%
Actions en circulation (diluées)	64.9	64.9	73.2	73	72.7	72
Variation des actions (H-H)	-10%	-10%	2%	1%	1%	30%
EPS (dilué)	-1.24	-1.03	-0.47	-0.83	1.14	-0.63
Croissance du EPS	-55%	65%	-28.99%	71%	-218%	-90%
Flux de trésorerie libre	-275	-30	-59	-96	-89	-84
Flux de trésorerie libre par action	--	--	--	--	--	--
Marge brute	--	--	--	--	--	--
Marge opérationnelle	-43.89%	-788.88%	-104.87%	-322.72%	37.76%	-98.3%
Marge bénéficiaire	-30.53%	-744.44%	-85.36%	-277.27%	43.61%	-76.27%
Marge du flux de trésorerie libre	-104.96%	-333.33%	-143.9%	-436.36%	-47.34%	-142.37%
EBITDA	-112	-71	-43	-71	71	-57
Marge EBITDA	-42.74%	-788.88%	-104.87%	-322.72%	37.76%	-96.61%
D&A pour le résultat opérationnel	3	0	0	0	0	1
EBIT	-115	-71	-43	-71	71	-58
Marge EBIT	-43.89%	-788.88%	-104.87%	-322.72%	37.76%	-98.3%
Taux d'imposition effectif	0%	0%	0%	0%	0%	0%

Follow-Up Questions

Arvinas Inc의 주요 재무제표는 무엇인가요?



최신 재무제표(Form-10K)에 따르면, Arvinas Inc의 총 자산은 $0이며, 순perte입니다.

ARVN의 주요 재무 비율은 무엇인가요?



Arvinas Inc의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.

Arvinas Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?



Le segment de revenus le plus important est Arvinas Inc, avec un chiffre d'affaires de Protein Degradation Therapies lors du dernier rapport de résultats. En termes géographiques, United States est le marché principal pour Arvinas Inc, avec un chiffre d'affaires de 262,600,000.

Arvinas Inc은 수익성이 있나요?



non, 최신 재무제표에 따르면 Arvinas Inc의 순perte은 $0입니다.

Arvinas Inc에 부채가 있나요?



non, Arvinas Inc의 부채는 0입니다.

Arvinas Inc의 발행 주식은 몇 주인가요?



Arvinas Inc의 총 발행 주식은 0주입니다.

Arvinas Inc (ARVN) Financier

Graphique du cours de l'action ARVN